Use of dPEG® Spacers in PNA Synthesis

Follow

Please note that the dPEG® products 5010 and 5011 have been discontinued.

“dPEG®” (discrete poly-(ethylene glycol) or discrete PEG) products, invented by QuantaBiodesign, like traditional PEGs, contain a hydrophilic, water-soluble backbone consisting of repeating ethylene oxide units; however, unlike traditional PEGs, each of the products represents a single compound with a unique, specific, single molecular weight. These products have been used for the modification of therapeutic macromolecules, as linkers in antibody-drug conjugates (ADCs), for bioconjugation of biologics, for surface modification, and in diagnostics, amongst other things.

dPEG® products convey the beneficial properties of traditional PEGs, such as increased water solubility, reduced aggregation, increased hydrodynamic volume, and reduced immunogenicity, but they do so without the complications of polydispersity and allow for the rational design of dPEG® conjugates and analysis of their structure-activity relationships. Two of the products have specific utility in PNA oligomer design.

While the AEEA linker (5005) is the most commonly used linker in PNA synthesis, it is possible to use the thiol modified dPEG® linkers, dPEG®₄-SATA-Acid (S-acetyl-dPEG®₄-acid) (5010) and SPDP-dPEG®₄-Acid (5011). These are particularly useful where a label is only reactive with a thiol and the use of Cys residues is not optimal, e.g. where this would interfere with the functionality of a PNA-peptide. They also have potential as a means of attaching PNA to gold surfaces via the thiol linker, and the in-built PEG spacer adds distance between the surface and the oligo in a similar way to that described by Anstaett et al.1 These can be incorporated either at the N-terminus or on a branching point incorporated as described above. The thiol linkers are coupled in the same way as the AEEA linker.

Both linkers are suitable for on-column conjugation where 5010 is deprotected using hydroxylamine or 5011 using TCEP.

5010

5011

Applicable to products 5001, 5002, 5003, 5004, 5005, 5010 and 5011.

Reference

  1. Synthesis of stable peptide nucleic acid-modified gold nanoparticles and their assembly onto gold surfaces, P. Anstaett, Y. Zheng, T. Thai, A.M. Funston, U. Bach and G. Gasser, Angew. Chem. Int. Ed., 52, 4217 –422, 2013. [Abstract]

dPEG® products are sold under licence from Quanta Biodesign, Ltd, (Plain City, OH), are sold for laboratory use only and are not intended to be used for any other purposes, including but not limited to, in vitro diagnostic purposes, in foods, drugs, medical devices, cosmetics or commercial use. A separate licensing agreement/supply agreement with Quanta BioDesign, Ltd. is required to use the products in applications beyond laboratory use. Customers are responsible to informing Quanta BioDesign, Ltd when products are being used beyond lab use. dPEG® technology is protected by US Patents #7,888,536 and 8,637,711 and US Patent Pending #2013/0052130. dPEG® is a registered trademark of Quanta BioDesign, Ltd.

Have more questions? Submit a request

Comments

Powered by Zendesk